Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology firm, has announced participation in the SVB Securities Global Biopharma Conference, with a corporate update scheduled for February 14, 2023, at 8:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology firm, has announced participation in the SVB Securities Global Biopharma Conference, with a corporate update scheduled for February 14, 2023, at 8:00 a.m. ET. The conference will take place virtually, allowing one-on-one investor meetings. Selecta focuses on its ImmTOR™ platform, developing therapies for autoimmune diseases and gene therapies.
For further details, interested parties can access an archived webcast on the company’s website. Selecta has multiple programs aimed at enzyme and gene therapies, emphasizing its role in enhancing biologic therapy efficacy.
Details
News Market Reaction – SELB
The recorded move for SELB in the trading session of this news was +2.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.
SVB Securities Global Biopharma Conference
Format: Corporate update and one-on-one investor meetings
Presentation Date: Tuesday, February 14, 2023
Presentation Time: 8:00 a.m. ET
Webcast: Click Here
To schedule a meeting with the Company, please contact your SVB Securities representative.
An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.